Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
grade A 16.99 1.01% 0.17
VCEL closed up 1.01 percent on Friday, November 16, 2018, on 69 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical VCEL trend table...

Date Alert Name Type % Chg
Nov 16 Wide Bands Range Expansion 0.00%
Nov 16 Overbought Stochastic Strength 0.00%
Nov 15 180 Bullish Setup Bullish Swing Setup 1.01%
Nov 15 Wide Bands Range Expansion 1.01%
Nov 15 Overbought Stochastic Strength 1.01%
Nov 14 Calm After Storm Range Contraction 4.88%
Nov 14 Outside Day Range Expansion 4.88%
Nov 14 Wide Bands Range Expansion 4.88%
Nov 14 Overbought Stochastic Strength 4.88%
Nov 13 Calm After Storm Range Contraction 3.35%

Older signals for VCEL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Is VCEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.51
52 Week Low 3.85
Average Volume 1,090,712
200-Day Moving Average 11.7867
50-Day Moving Average 13.51
20-Day Moving Average 13.666
10-Day Moving Average 16.033
Average True Range 1.072
ADX 36.47
+DI 34.0546
-DI 12.1252
Chandelier Exit (Long, 3 ATRs ) 14.294
Chandelier Exit (Short, 3 ATRs ) 13.726
Upper Bollinger Band 18.9055
Lower Bollinger Band 8.4265
Percent B (%b) 0.82
BandWidth 76.67935
MACD Line 1.159
MACD Signal Line 0.7396
MACD Histogram 0.4193
Fundamentals Value
Market Cap 557.66 Million
Num Shares 32.8 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -16.34
Price-to-Sales 2.75
Price-to-Book 10.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.60
Resistance 3 (R3) 18.53 17.92 18.33
Resistance 2 (R2) 17.92 17.51 17.96 18.24
Resistance 1 (R1) 17.46 17.26 17.69 17.53 18.15
Pivot Point 16.85 16.85 16.97 16.89 16.85
Support 1 (S1) 16.39 16.44 16.62 16.46 15.83
Support 2 (S2) 15.78 16.19 15.82 15.74
Support 3 (S3) 15.32 15.78 15.65
Support 4 (S4) 15.39